While unopposed conjugated equine estrogen (CEE) confers no protection against myocardial infarction (MI) or coronary death in generally healthy postmenopausal women between ages 50 and 79, when researchers looked only at women between 50 and 59, the story changed.
While unopposed conjugated equine estrogen (CEE) confers no protection against myocardial infarction (MI) or coronary death in generally healthy postmenopausal women between ages 50 and 79, when researchers looked only at women between 50 and 59, the story changed.
The findings come from the Women's Health Initiative and analysis of data on over 10,000 women aged 50 to 79 who had previously undergone hysterectomy. The women took either CEE 0.625 mg/d or placebo for approximately 7 years. During that time, 201 coronary events occurred in the group of women taking estrogen and 217 occurred in the group taking placebo (hazard ratio [HR] 0.95; nominal 95% confidence interval [CI], 0.79–1.16).
But when the researchers looked only at women aged 50 to 59, they found the HR for MI or coronary death in the group taking estrogen versus the group taking placebo to be 0.63 (nominal 95% CI; 0.36–1.08). They also found less frequent coronary revascularization (HR 0.55, nominal 95% CI; 0.35–0.86). But the low overall event rate in these younger women mandates that additional studies be conducted to determine whether any true protective benefit exists, according to the investigators.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More